NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

Not in the way you or HyGro state. There was no cherry picking to statistically create an advantage and it was not post hoc. In fact a third-party, blind to this trial other than the procedures and how it was run and the epidemiology of the disease chose other trials that have similar statistics including for residual disease and partial resection. Total resection is a goal, basically very difficult ti ultimately achieve for this disease.

My answer explained it, you’re just reviving a tired argument by restating it as if you’re saying something new. You’re not.